Iovance's Amtagvi Granted Approval in Australia for Advanced Melanoma

Iovance Biotherapeutics announced that Australia's TGA approved Amtagvi (lifileucel) for previously treated advanced melanoma, marking the company's third marketing authorization for the therapy. This approval addresses a significant market need in Australia, which has the highest melanoma incidence globally, and strengthens Iovance's commercial position in the TIL therapy space.